ArticleiLIVER2025
Efficacy of DPMAS combined with PE in improving survival outcomes of patients with acute hepatitis E-induced liver failure: A retrospective cohort analysis.
Article in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Exploring the efficacy and safety profile of the use of a heparin-free integrated tandem pre-flushing method for DPMAS treatment in patients with liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Acute hepatitis E can progress to liver failure with high mortality and limited treatment options. This study aimed to evaluate the clinical efficacy and safety of the Double Plasma Molecular Adsorption System (DPMAS) combined with plasma exchange (PE) in individuals with acute hepatitis E-induced liver failure. Methods: A retrospective analysis was performed on hospitalized patients with acute hepatitis E-induced liver failure admitted from January 2011 to December 2023. Ninety-three patients were enrolled and assigned to either a control group ( Results: The treatment group demonstrated significantly greater improvement in liver function and coagulation parameters than the control group. MELD score reduction was more pronounced in the treatment group (-6.78 ± 2.45 vs. -2.59 ± 1.98, Conclusion: DPMAS combined with PE is a safe and effective therapeutic modality for acute hepatitis E-induced liver failure, improving liver function, reducing MELD scores, and enhancing survival outcomes. MELD score may serve as a valuable tool to guide treatment stratification and predict prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.